Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.44 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Cerebras Q1 EPS miss sends shares down 9% after-hours